Sandy Der

Sandy is an accomplished researcher in innate immunity, genomics and oncology with both academic and industry leadership experience.
Prior to joining Novatio, Sandy was Scientific Associate at the Princess Margaret Cancer Centre and University Health Network where he studied the genomic and molecular pathology of lung cancers and worked on the development of novel immunotherapies for treating lung cancer and leukemia.
In this capacity, Sandy co-invented prognostic, multi-gene classifiers for early-stage non-small cell lung cancer currently being commercialized by Helomics (Pittsburg, PA).
Previously, Sandy was Director of Research at GeneNews, a Toronto-based biotechnology firm, where he was involved in the development of blood-based molecular assays for several cancers.
Prior to this, Sandy was Assistant Professor at the Department of Laboratory Medicine and Pathobiology, University of Toronto where his lab was among the early adopters using genomic technologies to study human diseases including host immune responses to viral infections and cancer pathology.
Sandy completed his postdoctoral training in the Department of Cancer Biology at the Cleveland Clinic Foundation.
He earned his PhD in the Department of Medical Genetics at the University of Toronto studying host responses to HIV infection, and his BSc from the same institution in microbiology.